|
Delayed
Budapest S.E.
13:43:54 09/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 12,300.00 HUF | +0.82% |
|
+0.57% | +24.68% |
| 09-18 | EU Medicines Agency Panel Issues Positive Opinion on Gedeon Richter's Arthritis Drug | MT |
| 08-11 | Gedeon Richter PLC, Q2 2026 Earnings Call, Aug 07, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Generic Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 6.81B | |||||
| 1,043B | |||||
| 618B | - | ||||
| 481B | |||||
| 351B | |||||
| 338B |
- Stock Market
- Stocks
- RICHTER Stock
- Charts Gedeon Richter
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
